Reviva pharmaceuticals announces 80% global enrollment update for pivotal phase 3 recover study evaluating brilaroxazine for schizophrenia

- enrollment ongoing at multiple sites in the us, europe, and asia - - multifaceted activity of serotonin-dopamine stabilizer brilaroxazine supports potential for improvement in schizophrenia symptoms as well as accompanying neuroinflammation - - topline data for phase 3 recover study expected in q3 2023 - cupertino, calif., june 22, 2023 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph) (“reviva” or the “company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), cardiovascular, metabolic, and inflammatory diseases, today announced over 80% of patients have been enrolled in the pivotal phase 3 recover study evaluating brilaroxazine for the treatment of schizophrenia.
RVPH Ratings Summary
RVPH Quant Ranking